FDA Inspection
Fagron Compounding ServicesFagron Compounding Services – FDA Inspection, Mar 24, 2022
Record Details
This FDA Inspection record concerns Fagron Compounding Services, with an inspection on March 24, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Fagron Compounding Services
- Inspection Date
- March 24, 2022
- Product Type
- Drugs
View Company Profile
ID · dc953c9d-47eb-4c7c-946a-55e29c50898e
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1167657
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
5- 21 CFR 211.42(c)(10)(v)Cleaning System
- 21 CFR 211.165(a)Testing and release for distribution
- 21 CFR 211.160(a)Lab controls established, including changes
- 21 CFR 211.100(a)Absence of Written Procedures
- 21 CFR 211.110(a)Written in-process control procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Fagron Compounding Services
4| Date | Classification | Office | Project area |
|---|---|---|---|
| August 8, 2025 | Not classified | Kansas City District Office | Drug Quality Assurance |
| June 28, 2024 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 21, 2019 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 21, 2016 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Fagron Compounding Services
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.